Demo Data from EDBT 2026 / reviewers in the wild / expert
Peter Hurwitz
dblp:253/1516
· DBLP profile ↗
1ranked-venue papers
0as first author
1since 2021 · last 2023
—ORCID · unresolved
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1 · 1 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 2 heaviest of 2, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology
biomarker discovery |
0.7 | 1 | 2023 | MEvA-X: a hybrid multiobjective evolutionary tool using an XGBoost classifier for biomarkers discovery on biomedical datasets · Bioinform. 2023 |
Bioinformatics and computational biology
feature selection |
0.7 | 1 | 2023 | MEvA-X: a hybrid multiobjective evolutionary tool using an XGBoost classifier for biomarkers discovery on biomedical datasets · Bioinform. 2023 |
Methods — techniques the papers use, named apart from their topics
multiobjective evolutionary algorithms · 0.7ensemble learning · 0.7XGBoost · 0.7
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2023 | MEvA-X: a hybrid multiobjective evolutionary tool using an XGBoost classifier for biomarkers discovery on biomedical datasetsabstractMOTIVATION: Biomarker discovery is one of the most frequent pursuits in bioinformatics and is crucial for precision medicine, disease prognosis, and drug discovery. A common challenge of biomarker discovery applications is the low ratio of samples over features for the selection of a reliable not-redundant subset of features, but despite the development of efficient tree-based classification methods, such as the extreme gradient boosting (XGBoost), this limitation is still relevant. Moreover, existing approaches for optimizing XGBoost do not deal effectively with the class imbalance nature of the biomarker discovery problems, and the presence of multiple conflicting objectives, since they focus on the training of a single-objective model. In the current work, we introduce MEvA-X, a novel hybrid ensemble for feature selection (FS) and classification, combining a niche-based multiobjective evolutionary algorithm (EA) with the XGBoost classifier. MEvA-X deploys a multiobjective EA to optimize the hyperparameters of the classifier and perform FS, identifying a set of Pareto-optimal solutions and optimizing multiple objectives, including classification and model simplicity metrics. RESULTS: The performance of the MEvA-X tool was benchmarked using one omics dataset coming from a microarray gene expression experiment, and one clinical questionnaire-based dataset combined with demographic information. MEvA-X tool outperformed the state-of-the-art methods in the balanced categorization of classes, creating multiple low-complexity models and identifying important nonredundant biomarkers. The best-performing run of MEvA-X for the prediction of weight loss using gene expression data yields a small set of blood circulatory markers which are sufficient for this precision nutrition application but need further validation. AVAILABILITY AND IMPLEMENTATION: https://github.com/PanKonstantinos/MEvA-X. Konstantinos Panagiotopoulos, Aigli Korfiati, Konstantinos Theofilatos, Peter Hurwitz, Marco Agostino Deriu, Seferina Mavroudi |
Bioinform. | 4 |